An analysis of abnormalities in the B cell receptor repertoire in patients with systemic sclerosis using high-throughput sequencing.

B cell receptor CDR3 High-throughput sequencing Mechanisms Systemic sclerosis

Journal

PeerJ
ISSN: 2167-8359
Titre abrégé: PeerJ
Pays: United States
ID NLM: 101603425

Informations de publication

Date de publication:
2020
Historique:
received: 13 09 2019
accepted: 09 12 2019
entrez: 29 1 2020
pubmed: 29 1 2020
medline: 29 1 2020
Statut: epublish

Résumé

Systemic sclerosis is a chronic multisystem autoimmune disease that is associated with polyclonal B cell hyperreactivity. The CDR3 of BCRs is the major site of antigen recognition. Therefore, we analyzed the BCR repertoire of patients with SSc. The BCR repertoires in 12 subjects including eight SSc patients and four healthy controls were characterized by high-throughput sequencing, and bioinformatics analysis were studied. The average CDR3 length in the SSc group was significantly shorter. The SSc patient displayed more diverse BCR. Moreover, SSc patients with mild skin sclerosis, anti-Scl70, interstitial lung disease or female sex were more diversified. B cells from the SSc patients showed a differential V and J gene usage. SSc patients had distinct BCR repertoires.These findings reflected the differences of BCR repertoires between SSc patients and controls. The higher-usage genes for the BCR sequence might be potential biomarkers of B cell-targeted therapies or diagnosis for SSc.

Identifiants

pubmed: 31988805
doi: 10.7717/peerj.8370
pii: 8370
pmc: PMC6968515
doi:

Banques de données

figshare
['10.6084/m9.figshare.9816224.v2']

Types de publication

Journal Article

Langues

eng

Pagination

e8370

Informations de copyright

©2020 Shi et al.

Déclaration de conflit d'intérêts

The authors declare there are no competing interests. Chenqing Zheng is employed by Shenzhen RealOmics (Biotech) Co.Ltd.

Références

Autoimmun Rev. 2015 Nov;14(11):1072-8
pubmed: 26209905
Genetics. 2015 Oct;201(2):459-72
pubmed: 26297338
Genes Immun. 2017 Jan;18(1):22-27
pubmed: 28053320
PLoS One. 2016 Mar 28;11(3):e0152464
pubmed: 27019362
Nat Immunol. 2015 Jul;16(7):755-65
pubmed: 26006014
Curr Opin Immunol. 2013 Oct;25(5):646-52
pubmed: 24140071
Ann Rheum Dis. 2015 Jun;74(6):1188-94
pubmed: 24442885
J Rheumatol. 1995 Jul;22(7):1281-5
pubmed: 7562759
Annu Rev Immunol. 2006;24:541-70
pubmed: 16551259
EBioMedicine. 2015 Nov 24;2(12):2070-9
pubmed: 26844287
Autoimmun Rev. 2012 Dec;12(2):114-20
pubmed: 22776784
Arthritis Rheum. 2007 Sep;56(9):3167-8
pubmed: 17763433
J Clin Invest. 1997 May 15;99(10):2488-501
pubmed: 9153293
J Immunol. 2000 Nov 15;165(10):5970-9
pubmed: 11067960
Immunity. 2000 Jul;13(1):37-45
pubmed: 10933393
J Exp Med. 2005 May 16;201(10):1659-67
pubmed: 15897279
Autoimmun Rev. 2012 May;11(6-7):A422-9
pubmed: 22172712
Springerplus. 2016 Jan 26;5:75
pubmed: 26844022
Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):30-36
pubmed: 27056741
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Autoimmun Rev. 2016 Feb;15(2):155-61
pubmed: 26497107
Autoimmun Rev. 2015 Mar;14(3):254-7
pubmed: 25462581
Arthritis Rheumatol. 2016 Feb;68(2):494-504
pubmed: 26414243
Autoimmun Rev. 2014 Sep;13(9):974-80
pubmed: 25067821
Trends Immunol. 2014 Oct 8;35(12):581-590
pubmed: 25306219
Autoimmun Rev. 2018 Mar;17(3):244-255
pubmed: 29343447
Immunology. 2018 Sep;155(1):3-17
pubmed: 29574826
J Dermatol. 2010 Jan;37(1):3-10
pubmed: 20175836
PLoS One. 2014 Nov 03;9(11):e111726
pubmed: 25364977
Ann Rheum Dis. 2007 Jun;66(6):754-63
pubmed: 17234652
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20216-21
pubmed: 19875695
Sci Immunol. 2017 Sep 29;2(15):
pubmed: 28963118
N Engl J Med. 2003 Oct 16;349(16):1526-33
pubmed: 14561795
Nat Biotechnol. 2014 Feb;32(2):158-68
pubmed: 24441474
J Clin Invest. 2002 Jun;109(11):1453-62
pubmed: 12045259
Nat Clin Pract Rheumatol. 2006 Dec;2(12):679-85
pubmed: 17133253
J Clin Pathol. 2005 Feb;58(2):178-84
pubmed: 15677539
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2703-8
pubmed: 10694576
Arthritis Rheum. 2008 Dec;58(12):3913-23
pubmed: 19035500
Ann Rheum Dis. 2014 Apr;73(4):756-62
pubmed: 23606709

Auteurs

Xiaodong Shi (X)

Rheumatology, First Hospital of Jilin University, Changchun, The People's Republic of China.

Tihong Shao (T)

Rheumatology, The First Affiliated Hospital of Anhui Medical University, Hefei, The People's Republic of China.

Feifei Huo (F)

Intensive Care Unit, First hospital of Jilin university, Changchun, The People's Republic of China.

Chenqing Zheng (C)

Shenzhen RealOmics (Biotech) Co.Ltd, Shenzhen, The People's Republic of China.

Wanyu Li (W)

Hepatology, First hospital of Jilin university, Changchun, The People's Republic of China.

Zhenyu Jiang (Z)

Rheumatology, First Hospital of Jilin University, Changchun, The People's Republic of China.

Classifications MeSH